Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

FDA Approves T-DXd Plus Pertuzumab for HER2+ Breast Cancer

December 15th 2025

The FDA approved T-DXd plus pertuzumab for the first-line treatment of unresectable or metastatic HER2-positive breast cancer.

Varegacestat Hits Phase 3 PFS End Point in Progressing Desmoid Tumors

December 15th 2025

Varegacestat improved progression-free survival vs placebo in patients with progressing desmoid tumors.

Bezuclastinib Shows Promise in Nonadvanced Systemic Mastocytosis

December 15th 2025

Bezuclastinib markedly improved symptoms and disease markers in nonadvanced systemic mastocytosis, showing durable benefit and a manageable safety profile.

Five Under 5: Top Oncology Videos for the Week of 12/7

December 14th 2025

The top 5 OncLive TV videos of the week cover insights in acute myeloid leukemia, follicular lymphoma, multiple myeloma, and Ph+ B-ALL.

The OncFive: Top Oncology Articles for the Week of 12/7

December 13th 2025

The FDA approved Akeega for use in BRCA2+ mCSPC, granted priority review to the sBLA for nivolumab plus AVD in classical Hodgkin lymphoma, and more.

FDA Approves Niraparib/Abiraterone Acetate Plus Prednisone for BRCA2+ mCSPC

December 12th 2025

The FDA has approved niraparib and abiraterone acetate with prednisone for BRCA2-mutated mCSPC.

Gedatolisib Plus Fulvestrant ± Palbociclib Is a Potential New SOC in HR+ PIK3CA Wild-Type Advanced Breast Cancer

December 12th 2025

Gedatolisib regimens showed PFS benefits irrespective of prior treatment duration in HR-positive, HER2-negative PIK3CA wild-type advanced breast cancer.

Camizestrant Switch Plus CDK4/6 Inhibition Continues to Outperform SOC in HR+/HER2– Breast Cancer

December 12th 2025

Camizestrant plus continued CDK4/6 inhibition led to clinically meaningful improvements in PFS, PFS2, TTFST, TTSSS, and chemotherapy/ADC-free survival vs SOC.

T-DXd Displays iDFS Benefit in Key Subgroups of HER2+ Early Breast Cancer With Residual Invasive Disease

December 11th 2025

T-DXd yielded iDFS improvements in HER2-positive early breast cancer with residual invasive disease, irrespective of HER2 expression of neoadjuvant chemotherapy type.

Maintenance Tucatinib Plus HP Extends Median PFS Beyond 2 Years in Advanced HER2+ Breast Cancer

December 11th 2025

Tucatinib plus HP improved median investigator-assessed PFS by 8.6 months as first-line maintenance vs HP alone in HER2-positive metastatic breast cancer.

Multimodal AI Model Prognostic for Long-Term Recurrence Following Treatment for Early Breast Cancer

December 10th 2025

The multimodal ICM+ model was prognostic for long-term recurrence following treatment in early breast cancer.

SEQUOIA Long-Term Data Continue to Support Zanubrutinib in Treatment-Naive CLL/SLL

December 9th 2025

Zanubrutinib shows sustained 6-year efficacy and safety in treatment-naive CLL/SLL, outperforming BR with durable PFS and high response rates.

Dual BCMA/CD19 CAR T-Cell Therapy AZD0120 Shows Promise for Multiple Myeloma

December 8th 2025

AZD0120 CAR T therapy shows rapid, deep responses and manageable safety in R/R myeloma, with ultra-fast manufacturing and strong early durability.

Pirtobrutinib Delivers Strong Responses and Durable Benefit in Pretreated CLL/SLL in Final BRUIN Analysis

December 7th 2025

Final data from the BRUIN trial show pirtobrutinib achieved an 81.6% ORR and durable outcomes with a favorable safety profile in previously treated CLL/SLL.

“Smart” Strategy of Up-front Targeted Therapy Reduces Need for Chemo in LBCL

December 7th 2025

Treating with targeted therapy for the first 4 cycles showed potential curative intent without impacting patient response to subsequent chemotherapy.

Revumenib Plus Decitabine/Cedazuridine and Venetoclax Proves Efficacious in Newly Diagnosed AML

December 7th 2025

The SAVE regimen shows high response and MRD negativity rates in patients with AML, but myelosuppression and infectious complications remain key concerns.

Epcoritamab Plus R-mini-CHOP May Aid in Treatment of Older Patients with First-Line DLBCL

December 7th 2025

Epcoritamab plus R-mini-CHOP delivered deep responses with manageable safety in elderly, high-risk patients with newly diagnosed DLBCL.

Rusfertide Continues to Show Strong Results for Polycythemia Vera

December 6th 2025

Rusfertide sustained hematocrit control and sharply reduced phlebotomy need through week 52 in PV, showing durable efficacy and a consistent safety profile.

Elranatamab Plus Iberdomide Shows Early Efficacy in R/R Multiple Myeloma

December 6th 2025

Elranatamab plus iberdomide showed a 95.5% response rate in patients with BCMA-naive relapsed/refractory myeloma per early MagnetisMM-30 data.

Cretostimogene Grenadenorepvec Shows Efficacy in Papillary-Only, BCG-Unresponsive NMIBC

December 6th 2025

Cretostimogene grenadenorepvec shows durable activity in BCG-unresponsive papillary-only NMIBC with no progression to MIBC and favorable tolerability.